AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33721213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 33721289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic Drug Scale (ADS)
Number of subjects: 837
Study 33721289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic Risk Scale (ARS)
Number of subjects: 837
Study 33721289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic Cognitive Burden Scale (ACBS)
Number of subjects: 837
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among people who never used injecting drugs
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among PWIDs without OAT
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among PWIDs with OAT
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) for recent drug users
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) among recent drug users
Number of subjects: 336
Study 33721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) overall
Number of subjects: 336
Study 33721837 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 1000 IU single dose
Number of subjects: 6
Study 33721875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam premedication (N = 749 after matching)
Number of subjects: 1266
Study 33721875 — intervention group
Group type: COMPARATOR
Intervention: No midazolam premedication (N = 357 after matching)
Number of subjects: 1266
Study 33722059 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Ejection Fraction (RVEF) measurement
Number of subjects: 7131
Study 33722066 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 33722066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 33722066 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 33722066 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33722290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 3011
Study 33722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sequencing of a 91 gene panel (n=67) and whole-exome sequencing (n=30)
Number of subjects: 123
Study 33722295 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 123
Study 33722305 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart HR+ wearable device measuring floors climbed, total steps, and total distance travelled for 7 days prior to surgery
Number of subjects: 49
Study 33722701 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy including steroids (dexamethasone)
Number of subjects: 270
Study 33722855 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-999 (a novel antibody-drug conjugate targeting Globo H)
Number of subjects: 0
Study 33722855 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-999
Number of subjects: 0
Study 33722860 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye method for measuring gut transit time
Number of subjects: 863
Study 33722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System with adjunctive coiling
Number of subjects: 116
Study 33722996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateropulsion (pusher syndrome)
Number of subjects: 220
Study 33722996 — intervention group
Group type: EXPERIMENTAL
Intervention: Body tilt, pushing, and resistance
Number of subjects: 220
Study 33722996 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralesional visual vertical (VV)
Number of subjects: 220
Study 33723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 min)
Number of subjects: 46
Study 33723260 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC) combined with bevacizumab (Bev), cyclophosphamide (Cy), acetylsalicylic acid (ASA), and low-dose interleukin (IL)-2
Number of subjects: 0
Study 33723260 — intervention group
Group type: EXPERIMENTAL
Intervention: OCDC-Bev-Cy regimen
Number of subjects: 0
Study 33723462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0
Study 33723507 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 100 mcg/kg
Number of subjects: 32
Study 33723507 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 200 mcg/kg
Number of subjects: 32
Study 33723507 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus ivermectin 400 mcg/kg
Number of subjects: 32
Study 33723507 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 32
Study 33723724 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-117 (16 mg daily for GI cancers; 24 mg on a 4 days on/3 days off schedule for non-GI cancers)
Number of subjects: 13
Study 33724063 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton MR Spectroscopy in BAT
Number of subjects: 21
Study 33724066 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 0
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of frailty score
Number of subjects: 604
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty predicts death one year after elective cardiac surgery test
Number of subjects: 604
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons score
Number of subjects: 604
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: European System for Cardiac Operative Risk Evaluation
Number of subjects: 604
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment added to existing risk scores
Number of subjects: 604
Study 33724366 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment
Number of subjects: 604
Study 33724632 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (damoctocog alfa pegol); prophylactic treatment twice weekly, every 5 days or every 7 days for ≥50 exposure days.
Number of subjects: 73
Study 33724867 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33725199 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and emerging therapies for cardiac amyloidosis
Number of subjects: 0
Study 33725209 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hypercapnia (defined as an arterial partial pressure of carbon dioxide, PaCO2) present in 39 patients (59.1%)
Number of subjects: 66
Study 33725209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia during the monitoring period
Number of subjects: 66
Study 33725322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (100, 200, 300 µg)
Number of subjects: 36
Study 33725322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (up to 300 µg)
Number of subjects: 36
Study 33725363 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HMGB1 levels
Number of subjects: 100
Study 33725363 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6-MWT)
Number of subjects: 100
Study 33725363 — intervention group
Group type: EXPERIMENTAL
Intervention: handgrip-strength test (HST)
Number of subjects: 100
Study 33725363 — intervention group
Group type: EXPERIMENTAL
Intervention: timed-stands test (TST)
Number of subjects: 100
Study 33725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Current follow-up schedule with 3-monthly endoscopy and MRI in the first year and 6-monthly thereafter
Number of subjects: 304
Study 33725387 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical follow-up schedules
Number of subjects: 304
Study 33725672 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational approaches to decode grasping force and velocity level from intraneural peripheral signals
Number of subjects: 0
Study 33725747 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients
Number of subjects: 162
Study 33725747 — intervention group
Group type: COMPARATOR
Intervention: BC survivors
Number of subjects: 162
Study 33726776 — intervention group
Group type: EXPERIMENTAL
Intervention: UDI-6 Total Score of 33.33
Number of subjects: 205
Study 33726776 — intervention group
Group type: EXPERIMENTAL
Intervention: IIQ-7 Total Score of 9.52
Number of subjects: 205
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids for critical COVID-19
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake self-proning
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction systems
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone ventilation (for 16-24 hours per day)
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding delay in extubation
Number of subjects: 39
Study 33726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of tracheostomy
Number of subjects: 39
Study 33726819 — intervention group
Group type: COMPARATOR
Intervention: Positive end expiratory pressure titration
Number of subjects: 39
Study 33726819 — intervention group
Group type: COMPARATOR
Intervention: Choice of personal protective equipment
Number of subjects: 39
Study 33726855 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest protocol
Number of subjects: 44
Study 33726855 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44
Study 33727121 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAR present (21% of patients, n = 33)
Number of subjects: 155
Study 33727235 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 1933
Study 33727235 — intervention group
Group type: COMPARATOR
Intervention: Other non-invasive oxygen strategy
Number of subjects: 1933
Study 33727626 — intervention group
Group type: EXPERIMENTAL
Intervention: Current URI symptoms (mild severity)
Number of subjects: 256
Study 33727626 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence and severity of URI
Number of subjects: 256
Study 33727862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive and highly sensitive responders to warfarin
Number of subjects: 2508
Study 33727862 — intervention group
Group type: COMPARATOR
Intervention: Normal responders to warfarin
Number of subjects: 2508
Study 33727901 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 0
Study 33727901 — intervention group
Group type: COMPARATOR
Intervention: valsartan (target dose, 160 mg twice daily)
Number of subjects: 0
Study 33727901 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 0
Study 33728434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted seasonal influenza vaccine
Number of subjects: 65
Study 33728434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax23 (PPV23)
Number of subjects: 65
Study 33728493 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser microgrooved surface (LMS) healing and prosthetic abutments
Number of subjects: 24
Study 33728493 — intervention group
Group type: COMPARATOR
Intervention: Machined surface (MS) healing and prosthetic abutments
Number of subjects: 24
Study 33728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (Q2W) intravenously (IV)
Number of subjects: 548
Study 33728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (Q3W) IV
Number of subjects: 548
Study 33728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (both dosing regimens)
Number of subjects: 548
Study 33728583 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 1522
Study 33728583 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1522
Study 33728588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMAs)
Number of subjects: 0
Study 33728588 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK inhibition targeting the RAS-pathway
Number of subjects: 0
Study 33728588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HMAs
Number of subjects: 0
Study 33728588 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of splicing, CD123/dendritic cell axis, GM-CSF progenitor cell hypersensitivity, JAK/STAT pathway targeting
Number of subjects: 0
Study 33729162 — intervention group
Group type: COMPARATOR
Intervention: Version 1 of the Consilium Care app
Number of subjects: 192
Study 33729162 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 2 of the Consilium Care app
Number of subjects: 192
Study 33729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based shared decision-making tool
Number of subjects: 0
Study 33729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA stimulation for 30 minutes per session, 30 sessions)
Number of subjects: 60
Study 33729165 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (brief period of stimulation to mimic sensations)
Number of subjects: 60
Study 33729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 60
Study 33729165 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 33729718 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist for Early Recognition and Treatment of Acute Illness and Injury implementation
Number of subjects: 4256
Study 33730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived social support (measured by FACIT-F) without depressive symptoms
Number of subjects: 1779
Study 33730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived social support (measured by FACIT-F) with depressive symptoms
Number of subjects: 1779
Study 33730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1779
Study 33730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of social support
Number of subjects: 1779
Study 33730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1779
Study 33730173 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33730336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 11051
Study 33730360 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
Number of subjects: 0
Study 33730360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA antibody-drug conjugate (belantamab mafodotin)
Number of subjects: 0
Study 33730360 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel targets and constructs (bispecific antibodies against BCMA, GPRC5D, FCRH5)
Number of subjects: 0
Study 33730360 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-based therapy
Number of subjects: 0
Study 33730422 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 7249
Study 33730422 — intervention group
Group type: COMPARATOR
Intervention: No assisted hatching
Number of subjects: 7249
Study 33730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR)
Number of subjects: 337
Study 33730841 — intervention group
Group type: COMPARATOR
Intervention: Bruton's tyrosine kinase inhibitors
Number of subjects: 337
Study 33730841 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP-based prognostic models
Number of subjects: 337
Study 33730841 — intervention group
Group type: COMPARATOR
Intervention: Established prognostic factors (including TP53 and IGHV gene mutation status)
Number of subjects: 337
Study 33730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent prognostic impact of treatment, β2-microglobulin and del(17p)
Number of subjects: 337
Study 33730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent prognostic impact of treatment, del(11q), del(17p) and SF3B1 mutation
Number of subjects: 337
Study 33730844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily until disease progression or intolerance
Number of subjects: 60
Study 33730844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 60
Study 33731014 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation at investigator teleconferences
Number of subjects: 766
Study 33731014 — intervention group
Group type: EXPERIMENTAL
Intervention: Public holidays
Number of subjects: 766
Study 33731014 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching 80% of the site's recruitment target
Number of subjects: 766
Study 33731212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored discharge teaching by trained teaching nurses
Number of subjects: 0
Study 33731212 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies from the Theoretical Domains Framework and the Behavior Change Wheel
Number of subjects: 0
Study 33731219 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP)
Number of subjects: 88
Study 33731219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 88
Study 33731219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PAP and mindfulness
Number of subjects: 88
Study 33731219 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study 33731327 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological testing for SARS-CoV-2
Number of subjects: 2603
Study 33731327 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms in children
Number of subjects: 2603
Study 33731327 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering of seropositive children
Number of subjects: 2603
Study 33731327 — intervention group
Group type: EXPERIMENTAL
Intervention: Class level variance in seropositivity
Number of subjects: 2603
Study 33731366 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatin accessibility and gene expression analysis using ATAC-seq on biobanked specimens.
Number of subjects: 0
Study 33731366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancer activity analysis.
Number of subjects: 0
Study 33731384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiatal hernia (HH) identified via non-contrast CT
Number of subjects: 3200
Study 33731384 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use
Number of subjects: 3200
Study 33731384 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year follow-up of 75 participants with HH
Number of subjects: 3200
Study 33731427 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone follow-up at 30 days
Number of subjects: 0
Study 33731427 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone follow-up at 30 days, 60 days, 6 months, and 12 months
Number of subjects: 0
Study 33731738 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) radiomics
Number of subjects: 59
Study 33731738 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted early responders (ER)
Number of subjects: 59
Study 33731738 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted late responders (LR)
Number of subjects: 59
Study 33731738 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted persistent/progressive disease (PD)
Number of subjects: 59
Study 33731806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrology follow-up
Number of subjects: 2041
Study 33731806 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physician or pediatrician follow-up
Number of subjects: 2041
Study 33731806 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nephrology specialist follow-up
Number of subjects: 2041
Study 33731806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2-3 AKI nephrology follow-up
Number of subjects: 2041
Study 33731806 — intervention group
Group type: COMPARATOR
Intervention: Inpatient nephrology consult
Number of subjects: 2041
Study 33731806 — intervention group
Group type: COMPARATOR
Intervention: Kidney admission diagnosis
Number of subjects: 2041
Study 33731806 — intervention group
Group type: COMPARATOR
Intervention: AKI non-recovery by discharge
Number of subjects: 2041
Study 33731991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 4819
Study 33732196 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching to psychotherapy preference
Number of subjects: 0
Study 33732196 — intervention group
Group type: COMPARATOR
Intervention: Standard psychotherapy
Number of subjects: 0
Study 33732242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary oxalate loading
Number of subjects: 0
Study 33732242 — intervention group
Group type: COMPARATOR
Intervention: CaOx stone formers
Number of subjects: 0
Study 33732242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate
Number of subjects: 0
Study 33732892 — intervention group
Group type: EXPERIMENTAL
Intervention: μ-opioid agonist buprenorphine
Number of subjects: 120
Study 33732892 — intervention group
Group type: EXPERIMENTAL
Intervention: μ-opioid antagonist naltrexone
Number of subjects: 120
Study 33732892 — intervention group
Group type: COMPARATOR
Intervention: inert pill
Number of subjects: 120
Study 33732892 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (TBS)
Number of subjects: 120
Study 33732892 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous TBS
Number of subjects: 120
Study 33732892 — intervention group
Group type: COMPARATOR
Intervention: sham TBS
Number of subjects: 120